Immunotherapy tested as new hope for rare, Tough-to-Treat cancers
NCT ID NCT02721732
Summary
This study tested whether the immunotherapy drug pembrolizumab could help control the growth of rare, advanced cancers that have spread or cannot be removed by surgery. It involved 157 patients with specific rare tumor types who had already tried standard treatments. The goal was to see if the drug, which works by boosting the body's immune system to fight cancer, could stop or slow the disease for a meaningful period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SKIN SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.